medigraphic.com
ISSN 1561-302X (Print)

2021, Number 4

<< Back Next >>

Rev cubana med 2021; 60 (4)

Novel aspects of COVID-19

Bacardi SE

Language: Spanish
References: 23
Page: 1-19
PDF size: 320.14 Kb.


ABSTRACT

Introduction: SARS-CoV-2 is the causative agent of COVID-19, which has claimed the lives of thousands of people in the world after its onset in Wuhan in 2019. An investigation was carried out on the characteristics of Covid-19 based on in the threat that this disease represents for the Republic of Cuba.
Objective: To describe the main characteristics of the virus, its antecedents and the various clinical manifestations, clinical and laboratory evolution and diagnosis, and the behavior to be followed in these patients and the care to be observed in the person.
Method: A bibliographic review of the main articles published in the specialized press was developed, through Pubmed, Hinari, SciELO, Scholar Google search engines, 23 articles were chosen.
Conclusions: Covid-19 is a disease with high contagion and non-negligible mortality, for which urgent measures of prevention and treatment of the patients must be taken.


REFERENCES

  1. Bonilla Aldana DK, Villamil Gómez WE, Rabaan AA, Rodríguez Morales AJ. Unanueva zoonosis viral de preocupación global: COVID-19, enfermedad porcoronavirus 2019. Iatreia. 2020[acceso: 12/03/2020]. Disponible en:https://www.researchgate.net/publication/339416296_Una_nueva_zoonosis_viral_de_preocupacion_global_COVID-19_enfermedad_por_coronavirus_2019

  2. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus Infections and InmuneResponses. J Med Virol. 2020;1-9. DOI: https://doi.org/10.1002/jmv.25685

  3. Bonilla Aldana DK, Suárez JA, Franco Paredes C, Vilcarromero S, Mattar S,Gómez Marin JE, et al. Brazil burning! What is the potential impact of the Amazonwildfires on vector-borne and zoonotic emerging diseases? - A statement from aninternational experts meeting. Travel Med Infect Dis. 2019;31:101474. DOI:https://doi.org/10.1016/j.tmaid.2019.101474

  4. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat RevMicrobiol. 2019;17(3):181-92. DOI: https://doi.org/10.1038/s41579-018-0118-9

  5. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes ofpneumonia. Respirology. 2018;23(2):130-7. DOI:https://doi.org/10.1111/resp.13196

  6. Al-Tawfiq JA, Gautret P. Asymptomatic Middle East Respiratory SyndromeCoronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review. Travel Med Infect Dis. 2019;27:27-32. DOI:https://doi.org/10.1016/j.tmaid.2018.12.003

  7. Millan Oñate J, Rodríguez Morales AJ, Camacho Moreno G, Mendoza Ramírez H,Rodríguez Sabogal IA, Álvarez Moreno C. A new emerging zoonotic virus ofconcern: the 2019 novel Coronavirus (COVID-19). Infectio. 2020;24(3). DOI:https://doi.org/10.22354/in.v24i3.848

  8. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of globalhealth concern. Lancet. 2020;(20):30185-9. DOI: https://doi.org/10.1016/S0140-6736

  9. Rodríguez Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P.Going global – Travel and the 2019 novel coronavirus. Travel Med Infect Dis.2020:101578. DOI: https://doi.org/10.1016/j.tmaid.2020.101578

  10. Bonilla Aldana DK, Holguin Rivera Y, Cortes Bonilla I, Cardona Trujillo MC,García Barco A, Bedoya Arias HA, et al. Coronavirus infections reported byProMED. 2000-2020. Travel Med Infect Dis. 2020:101575. DOI:https://doi.org/10.1016/j.tmaid.2020.101575

  11. Villamil Gómez WE, Sanchez A, Gelis L, Silvera LA, Barbosa J, Otero-Nader O,et al. Fatal human coronavirus 229E (HCoV 229E) and RSV-Related pneumonia inan AIDS patient from Colombia. Travel Med Infect Dis. 2020:101573. DOI:https://doi.org/10.1016/j.tmaid.2020.101573

  12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395. DOI:https://doi.org/10.1016/S0140 6736(20)30183-5

  13. Liu SL, Saif L. Emerging Viruses without Borders: The Wuhan Coronavirus.Viruses. 2020;12(2). DOI: https://doi.org/10.3390/v12020130

  14. Biscayart C, Angeleri P, Lloveras S, Chaves T, Schlagenhauf P, RodríguezMorales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? - Interim recommendations January2020, from the Latin-American society for Travel Medicine (SLAMVI). Travel MedInfect Dis. 2020:101567. DOI: https://doi.org/10.1016/j.tmaid.2020.101567

  15. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020.https://doi.org/10.1111/tmi.13383

  16. Wang LF, Anderson DE. Viruses in bats and potential spillover to animals andhumans. Curr Opin Virol. 2019;34:79-89. DOI:https://doi.org/10.1016/j.coviro.2018.12.007

  17. Interim guidance. Surveillance case definitions for human infection with novelcoronavirus (nCoV). Who.int. 2020[acceso: 12/03/2020]. Disponible en:https://apps.who.int/iris/bitstream/handle/10665/332412/WHO-2019-nCoVSurveillance-2020.2-eng.pdf

  18. Bonilla Aldana DK, Quintero Rada K, Montoya Posada JP, Ramírez S, Paniz-Mondolfi A, Rabaan A, et al. SARS-CoV, MERS-CoV and now the 2019-novel CoV:Have we investigated enough about coronaviruses? - A bibliometric analysis.Travel Med Infect Dis. 2020. DOI: https://doi.org/0.1016/j.tmaid.2020.101566

  19. Lipsitch M, Phil D, Swerdlow DL, Finelli L. Defining the Epidemiology of COVID-19-Studies Needed. Nejm. 2020. DOI: https://doi.org/10.1056/NEJMp2002125

  20. Organización Mundial de la Salud. Infection prevention and control duringhealth care for probable or confirmed cases of Middle East respiratory syndromecoronavirus (MERS-CoV) infection. Organización Mundial de la Salud. 2019[acceso:12/03/2020]. Disponible en: https://apps.who.int/iris/handle/10665/17 4652

  21. Surveillance case definitions for human infection with novel coronavirus(nCoV) Who.int. 2020[acceso: 12/03/2020]. Disponible en:https://www.who.int/publications/m/item/surveillance-case-definitions-forhuman-infection-withnovel-coronavirus-(ncov)

  22. Definition 2. Suspected Case. Interim guidance. Who.int. 2020[acceso:12/03/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/332300/WHO-2019-nCoV-laboratory-2020.2-eng.pdf

  23. Laboratory biorisk management for laboratories handling human specimenssuspected or confirmed to contain novel coronavirus: Interim recommendations.Ginebra, Organización Mundial de la Salud. 2013[acceso: 11/03/2020]. Disponibleen:https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_Nove lCoronavirus_19Feb13.pdf




2020     |     www.medigraphic.com